Embrace and Quality of Life

Quality of Life in Epilepsy Patients Wearing a Biosensor for Seizure Detection Through Electrodermal Activity and Accelerometry - a Pilot Study

A prospective, open, randomized, pilot clinical trial which aims the assessment of quality of life (QOL) in epilepsy outpatients equipped with a wrist-worn biosensor that provides measures of electrodermal activity and accelerometry. These measures are used to automatically detect epileptic seizures that are transmitted to a mobile phone-based system for alerts and recording.

Inclusion Criteria:

• male or female aged >18 years old
• clearcut diagnosis of epilepsy without evidence of non epileptic psychogenic seizure
• primary tonic clonic seizures or focal seizures evolving to generalized tonic clonic convulsion
• seizure frequency > 1 seizure/month during the last three months
• signed the informed consent form
• own a mobile phone device compatible with the embrace apps
• able to use the device without help from caregivers

Exclusion Criteria:

• patients aged less than 18 years old
• epilepsy diagnosis remains uncertain
• evidence of psychogenic non epileptic seizures
• seizure frequency below 1/month during any of the three previous months
• past-history of nickel allergy and contact dermatitis
• did not sign the informed consent form
• does not own mobile phone device compatible with the embrace apps
• cognitive or behavioral impairment preventing compliance or correct use of the device and app.